Section 4 of 6
Clinical evidence
370 evidence topics · 66 sources
Study summaries
COMP005
Objective
Primary aim: single dose of COMP360 25 mg versus placebo with psychological support
Secondary aims: durability, long-term safety, and retreatment
Location and study date
Study dates in the registry record
| Milestone | Registry entry |
|---|---|
| Study start (actual) | “2023-01-24” |
| Primary completion (actual) | “2025-05-28” |
| Study completion (actual) | “2026-04-15” |
Number of sites: registry and Form 10-K
Study design
Phase 3 randomized, double-blind, placebo-controlled, parallel-group design
| Design element | Registry entry |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |
Parts A, B, and C as described in the 52-week release
Retreatment criteria in Parts B and C
Concomitant antidepressants permitted after Part A
Eligibility criteria
Key inclusion criteria
Key psychiatric exclusion criteria
Exclusions for prior neuromodulation, psychotherapy, and psilocybin exposure
Treatment
Study arms
| Arm | Registry description |
|---|---|
| Experimental | “25 mg COMP360 Psilocybin” |
| Placebo comparator | “Matched placebo” |
| Intervention | “COMP360 Psilocybin administered under supportive conditions” |
Dosing by study part
Psychological support and monitoring model in the trials
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Primary endpoint as defined by the sponsor
Key secondary endpoint: Sheehan Disability Scale at Week 6
Development and validation of the MADRS
“The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The inner-rater reliability of the new depression scale was high. Scores on the scale correlated significantly with scores on a standard rating scale for depression, the Hamilton Rating Scale (HRS), indicating its validity as a general severity estimate. Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FDA guidance on primary and secondary endpoints in MDD trials
FDA guidance on the timing of the primary endpoint and durability
European Medicines Agency guidance on rating scales
MADRS total score as the primary efficacy measure in FDA-approved labeling for esketamine in TRD
Outcomes named in the ICER draft scope
Minimal clinically important difference on the MADRS
“To identify the minimal clinically important difference (MCID) for the Montgomery-Asberg Depression Rating Scale (MADRS) in randomised studies of depression, and to cross-validate the estimated MCID.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MCID estimates for MADRS ranged from 1.6 to 1.9.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinically meaningful change on the MADRS and SDS in TRD
“Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively. Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The relationships between the CGI‐S and the MADRS, SDS and PHQ‐9 were established in a moderately severe TRD population and may not be generalizable to severely ill subjects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical meaning of MADRS response and remission thresholds
“Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If a state of almost complete absence of symptoms were required for a definition of remission, a MADRS total score would be <8, because such scores corresponded to a CGI-S score of 2 ('borderline mentally ill').” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No consensus has emerged regarding an appropriate cutoff for defining remission on the Montgomery-Asberg Depression Rating Scale (MADRS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Response and remission definitions used by the company
Statistical analysis description
Number of participants (Planned and analyzed)
Participants dosed in Part A
Participants analyzed at Week 6 in the 25 mg arm
Description of analysis sets
Efficacy analyses by study part
Results
Participant disposition
Randomized and dosed participants
Participants in the 25 mg arm at Week 6
Second administration in Part B
Entry into and dosing in open-label Part C
Baseline characteristics
Demographics
| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
|---|---|---|
| Female, n (%) | “93 (54.4)” | “47 (54.0)” |
| White, n (%) | “149 (87.1)” | “78 (89.7)” |
| Asian, n (%) | “11 (6.4)” | “4 (4.6)” |
| Black or African American, n (%) | “6 (3.5)” | “2 (2.3)” |
| American Indian or Alaska Native, n (%) | “0” | “1 (1.1)” |
| Other race, n (%) | “5 (2.9)” | “2 (2.3)” |
| Age, years, mean (SD) | “45.9 (13.4)” | “45.3 (14.4)” |
| Age, years, minimum and maximum | “19, 77” | “22, 72” |
| Age ≥65 years, n (%) | “15 (8.8)” | “11 (12.6)” |
| Prior psilocybin experience, n (%) | “5 (2.9)” | “5 (5.7)” |
| Prior psychedelic experience including psilocybin, n (%) | “8 (4.7)” | “6 (6.9)” |
| BMI, kg/m2, mean (SD) | “28.4 (6.2)” | “27.7 (6.1)” |
Treatment history and baseline MADRS
| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
|---|---|---|
| Failed treatments in current episode: 1, n (%) | “2 (1.2)” | “1 (1.1)” |
| Failed treatments in current episode: 2, n (%) | “114 (66.7)” | “62 (71.3)” |
| Failed treatments in current episode: 3, n (%) | “45 (26.3)” | “19 (21.8)” |
| Failed treatments in current episode: 4, n (%) | “10 (5.8)” | “4 (4.6)” |
| Failed treatments in current episode: 5, n (%) | “0” | “1 (1.1)” |
| Treatments withdrawn in screening: 0, n (%) | “58 (33.9)” | “26 (29.9)” |
| Treatments withdrawn in screening: 1, n (%) | “38 (22.2)” | “32 (36.8)” |
| Treatments withdrawn in screening: 2, n (%) | “50 (29.2)” | “21 (24.1)” |
| Treatments withdrawn in screening: more than 2, n (%) | “25 (14.6)” | “8 (9.2)” |
| MADRS total score at baseline, mean (SD) | “31.5 (5.5)” | “31.5 (5.9)” |
| Mild (11-19), n (%) | “1 (0.6)” | “2 (2.3)” |
| Moderate (20-30), n (%) | “73 (42.7)” | “33 (37.9)” |
| Severe (≥31), n (%) | “97 (56.7)” | “52 (59.8)” |
Depression diagnosis history
| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
|---|---|---|
| Length of current episode, months, mean (SD) | “34.1 (29.1)” | “38.6 (33.0)” |
| Current episode less than 1 year, n (%) | “30 (17.5)” | “20 (23.0)” |
| Current episode 1-2 years, n (%) | “52 (30.4)” | “19 (21.8)” |
| Current episode more than 2 years, n (%) | “89 (52.0)” | “48 (55.2)” |
| Lifetime depressive episodes, mean (SD) | “7.7 (10.9)” | “7.2 (7.6)” |
| Lifetime episodes 2-5, n (%) | “107 (62.6)” | “54 (62.1)” |
| Lifetime episodes 6-10, n (%) | “40 (23.4)” | “21 (24.1)” |
| Lifetime episodes more than 10, n (%) | “23 (13.5)” | “12 (13.8)” |
Efficacy results
Part A: primary endpoint, change in MADRS total score at Week 6
Part A: least squares mean differences in MADRS by visit
| Visit | COMP360 25 mg vs placebo, LS mean difference (95% CI), p-value |
|---|---|
| Day 2 | “-4.7 (-7.0, -2.3), p<0.001” |
| Week 1 | “-7.2 (-9.6, -4.8), p<0.001” |
| Week 3 | “-5.2 (-7.4, -2.9), p<0.001” |
| Week 6 (primary) | “-3.6 (-5.7, -1.5), p<0.001” |
Part A: post hoc analysis of participants with at least 25% MADRS reduction at Week 6
Part B: blinded follow-up and retreatment through Week 26
Part B: remission after a second dose among Week 6 responders who had not remitted
Part C: open-label 25 mg dose in participants originally randomized to 25 mg
Part C: first 25 mg dose in participants originally randomized to placebo
Part C: response and remission after the open-label 25 mg dose
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Safety summary through Week 26
Treatment-emergent adverse events in Part A, through Week 6
| Event | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
|---|---|---|
| Any TEAE up to Week 6 | “120 (70.2)” | “34 (39.1)” |
| Any serious TEAE up to Week 6 | “4 (2.3)” | “1 (1.1)” |
| Any TEAE with onset on day of dosing | “118 (69.0)” | “23 (26.4)” |
| Resolved within 1 day | “111 (64.9)” | “22 (25.3)” |
| Resolved after more than 1 and up to 2 days | “15 (8.8)” | “2 (2.3)” |
| Resolved after more than 2 days | “22 (12.9)” | “5 (5.7)” |
Treatment-emergent adverse events in Part A with incidence above 5%
| MedDRA preferred term | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
|---|---|---|
| Any TEAE | “86 (50.3)” | “12 (13.8)” |
| Headache | “42 (24.6)” | “10 (11.5)” |
| Nausea | “35 (20.5)” | “3 (3.4)” |
| Hallucination, visual | “24 (14.0)” | “0” |
| Anxiety | “14 (8.2)” | “2 (2.3)” |
| Dizziness | “10 (5.8)” | “2 (2.3)” |
| Illusion | “9 (5.3)” | “1 (1.1)” |
Treatment-emergent adverse events through Week 26
| Event | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
|---|---|---|
| Any TEAE up to Week 26 | “145 (84.8)” | “52 (59.8)” |
| Any serious TEAE up to Week 26 | “8 (4.7)” | “2 (2.3)” |
| Any TEAE with onset on day of dosing | “121 (70.8” | “25 (28.7)” |
| Resolved within 1 day | “115 (67.3)” | “24 (27.6)” |
| Resolved after more than 1 and up to 2 days | “16 (9.4)” | “2 (2.3)” |
| Resolved after more than 2 days | “22 (12.9)” | “5 (5.7)” |
| MedDRA preferred term (incidence above 10% in the 25 mg arm) | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
|---|---|---|
| Any TEAE | “145 (84.8)” | “52 (59.8)” |
| Headache | “61 (35.7)” | “16 (18.4)” |
| Nausea | “44 (25.7)” | “5 (5.7)” |
| Hallucination, visual | “27 (15.8)” | “0” |
| Anxiety | “22 (12.9)” | “3 (3.4)” |
Treatment-emergent serious adverse events through Week 26
| MedDRA preferred term | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
|---|---|---|
| Any TESAE | “8 (4.7)” | “2 (2.3)” |
| Suicidal ideation | “4 (2.3)” | “0” |
| Depression suicidal | “1 (0.6)” | “0” |
| Major depression | “0” | “1 (1.1)” |
| Cellulitis | “1 (0.6)” | “0” |
| Diverticulitis | “1 (0.6)” | “0” |
| Urinary tract infection bacterial | “0” | “1 (1.1)” |
| Clavicle fracture | “1 (0.6)” | “0” |
| Rib fracture | “1 (0.6)” | “0” |
| Pneumothorax | “1 (0.6)” | “0” |
| Anaphylactic reaction | “1 (0.6)” | “0” |
Suicidality: data safety monitoring board statement, June 2025
Suicidality: serious adverse events across COMP005 and COMP006
Study limitations
Summary: functional unblinding, placebo comparator, observed-case and open-label follow-up, preliminary data
COMP005 compared COMP360 25 mg with a matched placebo, and the company states that concerns about functional unblinding and expectancy bias could hinder the interpretability or regulatory acceptability of its trial data. A systematic review reports that psychedelic trials have generally not reported pre-trial expectancy or blinding success and argues that their effect sizes are likely over-estimated. No statistical analyses were performed after the Week 6 primary analysis: Part B and Part C results are observed data, the responder analysis is post hoc, and protocol-allowed antidepressants were permitted in Parts B and C. Part C was open-label and was entered by approximately 70% of participants. The results are preliminary, had not been reviewed by the FDA at the 2025 topline announcement, and are reported in company documents and congress abstracts.
Company-stated risks of functional unblinding and expectancy bias
Regulatory scrutiny of functional unblinding in the phase 3 program
Preliminary topline data not yet reviewed by FDA or published
Descriptive, observed-case, and post hoc analyses after Week 6
Open-label design of Part C
European Medicines Agency guidance on comparators, expectancy, and unblinding in psychedelic trials
Blinding and expectancy confounds in psychedelic trials
“We conduct systematic reviews of psychedelic RCTs using Medline, PsychInfo and EMBASE (Jan 1990 - Nov 2020) and show that currently reported psychedelic RCTs have generally not reported pre-trial expectancy, nor the success of blinding procedures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of studies with a drug control condition (80), 49 (61.2%) used an inert placebo control, 16 (20.0%) used active comparators, 12 (15.0%) used both, and 3 (3.8%) used only different active psychedelic doses as a control.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The majority (81/86; 94%) of studies were blinded, though only 14 (17.3%) included blind assessment; only 8 of these 14 studies assessed participants' blinding. Blinding success, assessed in highly varied ways, was generally poor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Blinding integrity may be compromised by perceived treatment efficacy and adverse effects, introducing bias into outcome assessments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend collecting data on treatment expectations alongside monitoring blinding integrity to more accurately interpret study results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Low control-group response in psilocybin depression trials
“In this meta-analysis of 17 acute-phase randomized clinical trials of psilocybin (n = 373), esketamine (n = 573), or SSRIs (n = 4014), patients receiving control treatments in psilocybin trials had significantly worse depression outcomes compared with those receiving control treatments in trials of esketamine or SSRIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin in trials for depression has been given in psychedelic doses, which risks making functional unblinding both immediate and prevalent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, since administration is usually supervised, unblinding may also extend to study personnel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparison with open-label antidepressants under equal unblinding conditions
“Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding, which biases results when comparing PAT with blinded interventions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Contrary to the first of 3 hypotheses, PAT (8 trials; 249 patients) was no more effective than open-label TAD treatment (16 open-label TAD trials; 7921 patients), with an estimated difference of 0.3 favoring open-label TADs (95% CI, -1.39 to 1.98; P = .73).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline and systematic review assessments of psilocybin trial methods
“Small sample sizes and functional unblinding were major limitations in all studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Future trials should publish trial protocol and SAPs, use clinician-rated outcomes accessed by a blinded rater, evaluate blinding of intervention, and consider measuring expectancy and therapeutic fidelity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limited long-term evidence on retreatment with psychedelics
COMP006
Objective
Registered objective
Objective of the second dose and the 10 mg arm
Location and study date
Sites and countries
Dates of the Part A and Part B results announcements
Study design
Phase 3, randomized, double-blind, dose-controlled parallel-group design
Three study parts over 52 weeks
Retreatment and concomitant antidepressants in Parts B and C
Eligibility criteria
Key inclusion criteria
Key exclusion criteria
Planned limit on prior psychedelic experience
Treatment
Retreatment doses in Parts B and C
Psychological support model
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Primary endpoint: change from baseline in MADRS total score at Week 6, 25 mg versus 1 mg
Key secondary endpoint at Week 9
Registered secondary endpoints
Sponsor's stated rationale for the MADRS
FDA guidance on primary endpoints in depression trials
MADRS total score as the primary efficacy measure in FDA-approved labeling for esketamine in treatment-resistant depression
Development and sensitivity to change of the MADRS
“Ratings on these 17 items for 64 patients participating in studies of four different antidepressant drugs were used to create a depression scale consisting of the 10 items which showed the largest changes with treatment and the highest correlation to overall change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinically meaningful change in MADRS total score in treatment-resistant depression
“Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively. Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response and remission definitions on the MADRS
“Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor's definitions of remission and clinically meaningful reduction in COMP006
Rationale for the 1 mg active control and the 10 mg arm
FDA guidance on control groups in psychedelic drug trials
Use of a 1 mg psilocybin dose as an active control in earlier trials
“In previous clinical trials, a dose of 1 mg of psilocybin or a dose range of 1-3 mg/70 kg were used as an active control because these doses were believed not to produce significant psychedelic effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Active placebos, either low-dose psychedelics or alternative psychoactive medications (particularly those which induce a distinct but similarly profound psychoactive effect), likely provide a means of mitigating the expectancy effects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Actual enrollment in the registry record
Participants dosed, as reported by the company
Description of analysis sets
Safety analysis set
Efficacy analyses: least squares means in Part A and observed data in Part B
Results
Participant disposition
Participants dosed by arm
Participants in the 25 mg arm assessed at Week 6 and retreated in Part B
Results posting status in the registry
Baseline characteristics
Demographics
| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Female, n (%) | “160 (54.1)” | “68 (47.9)” | “69 (48.3)” |
| White, n (%) | “255 (86.1)” | “123 (86.6)” | “129 (90.2)” |
| Asian, n (%) | “14 (4.7)” | “6 (4.2)” | “6 (4.2)” |
| Black or African American, n (%) | “8 (2.7)” | “3 (2.1)” | “4 (2.8)” |
| American Indian or Alaska Native, n (%) | “0” | “0” | “1 (0.7)” |
| Other/not reported, n (%) | “19 (6.4)” | “10 (7.0)” | “3 (2.1)” |
| Age, years, mean (SD) | “46.2 (13.7)” | “42.9 (12.8)” | “45.5 (13.1)” |
| Age, min, max | “18, 79” | “19, 73” | “20, 75” |
| Age ≥65 years, n (%) | “29 (9.8)” | “9 (6.3)” | “13 (9.1)” |
| Prior psilocybin experience, n (%) | “12 (4.1)” | “5 (3.5)” | “5 (3.5)” |
| Prior psychedelic experience including psilocybin, n (%) | “20 (6.8)” | “8 (5.6)” | “9 (6.3)” |
| BMI, kg/m2, mean (SD) | “28.0 (6.2)” | “28.4 (6.4)” | “28.0 (6.5)” |
Treatment history and baseline MADRS
| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Failed treatments in current episode: 1, n (%) | “1 (0.3)” | “1 (0.7)” | “0” |
| Failed treatments in current episode: 2, n (%) | “190 (64.2)” | “105 (73.9)” | “98 (68.5)” |
| Failed treatments in current episode: 3, n (%) | “74 (25.0)” | “32 (22.5)” | “34 (23.8)” |
| Failed treatments in current episode: 4, n (%) | “29 (9.8)” | “4 (2.8)” | “11 (7.7)” |
| Failed treatments in current episode: 5, n (%) | “2 (0.7)” | “0” | “0” |
| Treatments withdrawn in screening: 0, n (%) | “68 (23.0)” | “30 (21.1)” | “36 (25.2)” |
| Treatments withdrawn in screening: 1, n (%) | “127 (42.9)” | “62 (43.7)” | “62 (43.4)” |
| Treatments withdrawn in screening: 2, n (%) | “68 (23.0)” | “34 (23.9)” | “31 (21.7)” |
| Treatments withdrawn in screening: more than 2, n (%) | “33 (11.1)” | “16 (11.3)” | “14 (9.8)” |
| MADRS total score at baseline, mean (SD) | “32.0 (5.8)” | “32.1 (5.8)” | “32.5 (5.4)” |
| Baseline MADRS subthreshold (≤10), n (%) | “2 (0.7)” | “0” | “0” |
| Baseline MADRS mild (11-19), n (%) | “0” | “0” | “0” |
| Baseline MADRS moderate (20-30), n (%) | “115 (38.9)” | “54 (38.0)” | “49 (34.3)” |
| Baseline MADRS severe (≥31), n (%) | “179 (60.5)” | “88 (62.0)” | “94 (65.7)” |
Depression diagnosis history
| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Length of current episode, months, mean (SD) | “45.5 (42.7)” | “37.7 (38.8)” | “38.4 (45.0)” |
| Length of current episode less than 1 year, n (%) | “53 (17.9)” | “37 (26.1)” | “30 (21.0)” |
| Length of current episode 1-2 years, n (%) | “73 (24.7)” | “35 (24.6)” | “41 (28.7)” |
| Length of current episode more than 2 years, n (%) | “170 (57.4)” | “70 (49.3)” | “72 (50.3)” |
| Lifetime depressive episodes, mean (SD) | “6.3 (7.4)” | “5.4 (6.6)” | “7.0 (12.5)” |
| Lifetime depressive episodes: 1, n (%) | “1 (0.3)” | “0” | “0” |
| Lifetime depressive episodes: 2-5, n (%) | “199 (67.2)” | “109 (76.8)” | “99 (69.2)” |
| Lifetime depressive episodes: 6-10, n (%) | “61 (20.6)” | “21 (14.8)” | “30 (21.0)” |
| Lifetime depressive episodes: more than 10, n (%) | “29 (9.8)” | “10 (7.0)” | “10 (7.0)” |
Baseline values that differ in the February 2026 presentation
| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Prior psilocybin experience, n (%) | “13 (4.4)” | “5 (3.5)” | “5 (3.5)” |
| Prior psychedelic experience including psilocybin, n (%) | “19 (6.4)” | “7 (4.9)” | “9 (6.3)” |
| BMI, kg/m2, mean (SD) | “28.0 (6.2)” | “28.6 (7.1)” | “27.8 (6.7)” |
| Failed treatments in current episode: 2, n (%) | “190 (64.2)” | “105 (73.9)” | “99 (69.2)” |
| Failed treatments in current episode: 3, n (%) | “74 (25.0)” | “32 (22.5)” | “33 (23.1)” |
| Treatments withdrawn in screening: 0, n (%) | “68 (23.0)” | “31 (21.8)” | “36 (25.2)” |
| Treatments withdrawn in screening: 1, n (%) | “127 (42.9)” | “61 (43.0)” | “62 (43.4)” |
| Treatments withdrawn in screening: 2, n (%) | “68 (23.0)” | “35 (24.6)” | “31 (21.7)” |
| Treatments withdrawn in screening: more than 2, n (%) | “33 (11.1)” | “15 (10.6)” | “14 (9.8)” |
| Lifetime depressive episodes: 2-5, n (%) | “198 (66.9)” | “109 (76.8)” | “99 (69.2)” |
Efficacy results
Part A primary endpoint: MADRS change at Week 6, 25 mg versus 1 mg
Part A: MADRS least squares mean differences by visit through Week 6, November 2026 presentation
| Visit | 25 mg vs 1 mg, LS mean difference (95% CI) | 25 mg vs 1 mg, P-value | 10 mg vs 1 mg, LS mean difference (95% CI) | 10 mg vs 1 mg, P-value |
|---|---|---|---|---|
| Day 2 | “-2.9 (-4.6, -1.2)” | “<0.001” | “-3.0 (-5.0, -1.0)” | “0.002” |
| Week 1 | “-5.0 (-7.0, -3.0)” | “<0.001” | “-3.5 (-5.9, -1.2)” | “0.001” |
| Week 3 | “-4.4 (-6.3, -2.5)” | “<0.001” | “-3.4 (-5.6, -1.2)” | “0.001” |
| Day 24 | “-5.0 (-7.1, -2.9)” | “<0.001” | “-4.9 (-7.4, -2.5)” | “<0.001” |
| Week 4 | “-4.8 (-6.9, -2.7)” | “<0.001” | “-4.9 (-7.3, -2.5)” | “<0.001” |
| Week 6 (primary) | “-3.8 (-5.8, -1.8)” | “<0.001” | “-2.5 (-4.8, -0.2)” | “0.017” |
Part A: 10 mg versus 1 mg at Week 6, as reported in February and September 2026
Part A key secondary endpoint: MADRS change at Week 9
| Visit | 25 mg vs 1 mg, LS mean difference (95% CI) | 25 mg vs 1 mg, P-value | 10 mg vs 1 mg, LS mean difference (95% CI) | 10 mg vs 1 mg, P-value |
|---|---|---|---|---|
| Week 6 (primary) | “-3.8 (-5.8, -1.8)” | “<0.001” | “-2.5 (-4.9, -0.2)” | “0.016” |
| Week 9 (secondary) | “-2.9 (-5.0, -0.9)” | “0.002” | “-2.6 (-5.0, -0.2)” | “0.016” |
Part A post hoc responder analysis at Week 6, 25 mg arm
Part B: MADRS change through Week 26
Part B: retreatment and remission after retreatment
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Part A safety summary
Part A treatment-emergent adverse events through Week 9
| Measure | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Any TEAE up to Week 9, n (%) | “274 (92.6)” | “125 (88.0)” | “116 (81.1)” |
| Any serious TEAE up to Week 9, n (%) | “6 (2.0)” | “1 (0.7)” | “5 (3.5)” |
| Any TEAE with onset on day of dosing, n (%) | “260 (87.8)” | “114 (80.3)” | “80 (55.9)” |
| Resolved ≤1 day, n (%) | “244 (82.4)” | “107 (75.4)” | “71 (49.7)” |
| Resolved >1 and ≤2 days, n (%) | “52 (17.6)” | “16 (11.3)” | “9 (6.3)” |
| Resolved >2 days, n (%) | “71 (24.0)” | “26 (18.3)” | “20 (14.0)” |
Part A TEAEs with incidence above 10%
| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Any TEAE, n (%) | “254 (85.8)” | “111 (78.2)” | “80 (55.9)” |
| Nausea, n (%) | “118 (39.9)” | “42 (29.6)” | “15 (10.5)” |
| Headache, n (%) | “108 (36.5)” | “43 (30.3)” | “41 (28.7)” |
| Anxiety, n (%) | “62 (20.9)” | “28 (19.7)” | “21 (14.7)” |
| Hallucination, visual, n (%) | “46 (15.5)” | “24 (16.9)” | “3 (2.1)” |
| Illusion, n (%) | “41 (13.9)” | “16 (11.3)” | “3 (2.1)” |
| Dizziness, n (%) | “41 (13.9)” | “21 (14.8)” | “9 (6.3)” |
| Fatigue, n (%) | “41 (13.9)” | “23 (16.2)” | “16 (11.2)” |
| Crying, n (%) | “35 (11.8)” | “13 (9.2)” | “4 (2.8)” |
| Blood pressure increased, n (%) | “31 (10.5)” | “6 (4.2)” | “4 (2.8)” |
Part A treatment-emergent serious adverse events
| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Any SAE, n (%) | “6 (2.0)” | “1 (0.7)” | “5 (3.5)” |
| Suicidal ideation, n (%) | “0” | “1 (0.7)” | “2 (1.4)” |
| Suicidal behaviour, n (%) | “0” | “0” | “1 (0.7)” |
| Syncope, n (%) | “1 (0.3)” | “0” | “1 (0.7)” |
| Major depression, n (%) | “1 (0.3)” | “0” | “0” |
| Anxiety, n (%) | “1 (0.3)” | “0” | “0” |
| Flashback, n (%) | “1 (0.3)” | “0” | “0” |
| Cervical spinal stenosis, n (%) | “1 (0.3)” | “0” | “0” |
| Renal neoplasm, n (%) | “0” | “0” | “1 (0.7)” |
| Pelvic pain, n (%) | “1 (0.3)” | “0” | “0” |
Safety summary through Week 26
Treatment-emergent adverse events through Week 26
| Measure | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Any TEAE up to Week 26, n (%) | “280 (94.6)” | “132 (93.0)” | “124 (86.7)” |
| Any serious TEAE up to Week 26, n (%) | “17 (5.7)” | “5 (3.5)” | “9 (6.3)” |
| Any TEAE with onset on day of dosing, n (%) | “265 (89.5)” | “119 (83.8)” | “88 (61.5)” |
| Resolved ≤1 day, n (%) | “255 (86.1)” | “113 (79.6)” | “78 (54.5)” |
| Resolved >1 and ≤2 days, n (%) | “60 (20.3)” | “22 (15.5)” | “12 (8.4)” |
| Resolved >2 days, n (%) | “80 (27.0)” | “32 (22.5)” | “21 (14.7)” |
| Nausea, n (%) | “133 (44.9)” | “50 (35.2)” | “18 (12.6)” |
| Headache, n (%) | “118 (39.9)” | “53 (37.3)” | “49 (34.3)” |
| Anxiety, n (%) | “83 (28.0)” | “38 (26.8)” | “29 (20.3)” |
| Hallucination, visual, n (%) | “51 (17.2)” | “27 (19.0)” | “5 (3.5)” |
| Fatigue, n (%) | “49 (16.6)” | “26 (18.3)” | “19 (13.3)” |
| Illusion or perceptual disturbance, n (%) | “48 (16.2)” | “19 (13.4)” | “4 (2.8)” |
| Dizziness, n (%) | “47 (15.9)” | “25 (17.6)” | “9 (6.3)” |
| Crying, n (%) | “41 (13.9)” | “15 (10.6)” | “6 (4.2)” |
| Blood pressure increased, n (%) | “35 (11.8)” | “10 (7.0)” | “4 (2.8)” |
Treatment-emergent serious adverse events through Week 26
| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Any TESAE, n (%) | “17 (5.7)” | “5 (3.5)” | “9 (6.3)” |
| Suicidal ideation, n (%) | “4 (1.4)” | “2 (1.4)” | “4 (2.8)” |
| Suicidal behaviour, n (%) | “0” | “0” | “1 (0.7)” |
| Suspected suicide, n (%) | “1 (0.3)” | “0” | “0” |
| Suicide attempt, n (%) | “0” | “0” | “1 (0.7)” |
| Syncope, n (%) | “1 (0.3)” | “0” | “1 (0.7)” |
| Major depression, n (%) | “1 (0.3)” | “0” | “0” |
| Anxiety, n (%) | “1 (0.3)” | “0” | “0” |
| Flashback, n (%) | “1 (0.3)” | “0” | “0” |
| Cervical spinal stenosis, n (%) | “1 (0.3)” | “0” | “0” |
| Renal neoplasm, n (%) | “0” | “0” | “1 (0.7)” |
| Pelvic pain, n (%) | “1 (0.3)” | “0” | “0” |
| Adjustment disorder with mixed disturbance of emotion and conduct, n (%) | “1 (0.3)” | “0” | “0” |
| Pneumonia, n (%) | “0” | “1 (0.7)” | “0” |
| Radius fracture, n (%) | “1 ( 0.3)” | “1 (0.7)” | “0” |
| Road traffic accident, n (%) | “1 ( 0.3)” | “0” | “0” |
| Tibia fracture, n (%) | “1 ( 0.3)” | “0” | “0” |
| Ulna fracture, n (%) | “1 ( 0.3)” | “0” | “0” |
| Alanine aminotransferase increased, n (%) | “1 ( 0.3)” | “0” | “0” |
| Aspartate aminotransferase increased, n (%) | “1 ( 0.3)” | “0” | “0” |
| Brain neoplasm, n (%) | “1 (0.3)” | “0” | “0” |
| Thyroid neoplasm, n (%) | “1 (0.3)” | “0” | “0” |
| Cerebrovascular accident, n (%) | “0” | “0” | “1 (0.7)” |
| Toxic encephalopathy, n (%) | “0” | “1 (0.7)” | “0” |
| Tremor, n (%) | “1 (0.3)” | “0” | “0” |
Study limitations
Summary: functional unblinding, low-dose comparator, post hoc and observed-case analyses, preliminary data
COMP006 used COMP360 1 mg as the comparator to address “some of the functional unblinding risks of an inert placebo-control”. FDA guidance states that functional unblinding can lead to expectation bias and that enrolling participants with prior psychedelic exposure raises the possibility of expectation bias; the planned limit for prior psychedelic experience in COMP006 was 15%. One analysis found that outcomes with extremely low dose psilocybin were better than placebo response in psychedelic trials (mean difference 3.96), and a review reported that psilocybin, LSD, and ayahuasca studies “frequently reported blinding failure values of more than 90%” among participants and raters. The responder analysis is post hoc, Part B results after Week 9 are observed data, and protocol-allowed antidepressants were permitted in Parts B and C. The company describes the 26-week results as preliminary and states that full results may not be consistent with them; the registry shows no results posted.
Functional unblinding and expectancy bias, as stated by the company
Release of Part A results while Part B remained blinded
Post hoc responder analyses, observed-case Part B data, and concomitant antidepressants
FDA guidance on functional unblinding and prior psychedelic exposure
Blinding failure in psychedelic trials: systematic reviews
“Functional unblinding was substantial: psilocybin, LSD, and ayahuasca studies frequently reported blinding failure values of more than 90% among participants and raters, inert placebo-controlled MDMA trials exceeded 85%, and ketamine trials rarely assessed blinding (17.9%) but showed improved preservation with midazolam vs saline controls. No control strategy consistently achieved ideal blinding.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Low-dose psilocybin as a comparator: response relative to inert placebo
“Notably, placebo response in antidepressant trials (3.79 (95% credibile interval 0.77 to 6.80)) and extremely low dose psilocybin (3.96 (0.61 to 7.17)) were better than placebo response in the psychedelic trials, with mean differences exceeding 3 and 95% credibile intervals that did not cross zero.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mitigation measures proposed in the literature
“We suggest that simple practical measures may be (and indeed already are) taken in psychedelic trials to partially mitigate the effects of expectancy and unblinding, such as independent raters and active placebos.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
COMP001
Objective
Protocol objectives: dose selection and superiority over 1 mg
Company statement of the trial objective
Role in the new drug application
Location and study date
Study dates and identifiers
| Item | Registry record |
|---|---|
| Other study ID | “COMP001” |
| Study start (actual) | “2019-03-01” |
| Primary completion (actual) | “2021-07-30” |
| Study completion (actual) | “2021-09-27” |
| Results first posted | “2023-04-24” |
Sites: registry record
Study design
Randomized, double-blind, dose-controlled design
“In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Registered design details
| Item | Registry record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |
Protocol design and visit schedule
Preparation, administration, and follow-up sessions
Screening period and antidepressant taper
Eligibility criteria
Registered eligibility criteria
| Item | Registry record |
|---|---|
| Inclusion | “Diagnosis of TRD” |
| Exclusion | “Other comorbidities” |
| Ages eligible | “18 Years and older” |
| Healthy volunteers | “No” |
Company definition of treatment-resistant depression
Inclusion criteria: protocol
Exclusion criteria: protocol
Treatment
Investigational product by arm
Administration session
Psychological support model
“which randomized 233 adults with TRD in 1:1:1 ratio to a single fixed-dose (25 mg, 10 mg, or 1 mg) of COMP360 that was administered with a well-defined psychological support model that emphasizes safety and self-directed enquiry” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As part of the COMP360 treatment, psychological support was provided to ensure the participants’ physical and psychological safety and consisted of three phases: preparation, administration, and integration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antidepressant washout before and after dosing
Rescue medication
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Primary endpoint definition
“The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Åsberg Depression Rating Scale (MADRS; range, 0 to 60, with higher scores indicating more severe depression).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Company rationale for the scale
Independent remote blinded rating
Scale construction and sensitivity to change
“The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory acceptance as a primary endpoint
Timing of the primary endpoint for a rapid-acting treatment
Clinically meaningful change in treatment-resistant depression
“Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal important difference estimates
“For both the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI-II), MID estimates range between 3 and 9 points, with estimates of 3-6 points likely being the most accurate.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Response and remission thresholds
“Secondary end points included response at week 3 (≥50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score ≤10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint hierarchy and multiplicity control
Time-to-event secondary endpoints in the protocol
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment and power
Actual enrollment: registry record
| Enrollment type | Participants |
|---|---|
| Actual | “233” |
Description of analysis sets
Analysis set definitions
Primary and secondary estimands
Analysis populations reported in the registry
Results
Participant disposition
Completion and withdrawals: company statement
Baseline characteristics
Demographics: registry results
Prior psilocybin experience
Baseline suicidality
Efficacy results
Primary endpoint: change in MADRS total score at Week 3
“Least-squares mean changes from baseline to week 3 in the score were -12.0 for 25 mg, -7.9 for 10 mg, and -5.4 for 1 mg; the difference between the 25-mg group and 1-mg group was -6.6 (95% confidence interval [CI], -10.2 to -2.9; P<0.001) and between the 10-mg group and 1-mg group was -2.5 (95% CI, -6.2 to 1.2; P = 0.18).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint: company statement
Observed MADRS change at Week 3: registry results
| Analysis set | 25 mg | 10 mg | 1 mg |
|---|---|---|---|
| Full analysis set, mean (SD) | “-12(12.98)” | “-8.9(10.94)” | “-6.8(11.10)” |
| Per-protocol set, mean (SD) | “-12(12.98)” | “-8.9(11.11)” | “-6.7(11.18)” |
Response, remission, and sustained response
“In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Post hoc analysis: antidepressant discontinuation before dosing
“Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Post hoc analysis: psychedelic experience and outcome
“The mean intensity of psychedelic effects was dose-related, but distributions of scores for different doses overlapped considerably.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the 25 mg dose, 5D-ASC dimensions Oceanic Boundlessness (Pearson correlation coefficient r = -0.508) and Visual Restructuralization (r = -0.516), and EBI (r = -0·637) were the variables with the strongest correlation to the Week 3 change from Baseline in MADRS score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Post hoc analysis: therapeutic alliance
“Change from Baseline to Week 3 MADRS scores showed weaker correlations with pre-dosing therapeutic alliance (-0.178) than with measures of the psychedelic experience: EBI (-0.637), Oceanic Boundlessness (-0.508), and Visual Restructuralization (-0.516).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The effects of the alliance itself on therapeutic efficacy were either limited or absent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Post hoc analysis: pretreatment characteristics and the psychedelic experience
“Dose was the strongest and most consistent predictor of the psychedelic experience.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Some pretreatment characteristics contributed weakly to subjective experiences.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory analysis: language-based prediction of response
“Two multinomial logistic regression models were fit to predict responder status at week 3 and through week 12. Cross-validation of these models resulted in 85% and 88% accuracy and AUC values of 88% and 85%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Patient-reported measures assessed
Week 3 patient-reported outcomes
“At Week 3, psilocybin 25 mg, compared with 1 mg, was associated with greater improvements from Baseline total scores in all measures. The 10 mg dose produced smaller effects across these measures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory endpoints and multiplicity
Safety results
Severity and timing of treatment-emergent adverse events
Serious adverse events through Week 12: registry results
| Event | 25 mg | 10 mg | 1 mg |
|---|---|---|---|
| Any serious adverse event | “5/79 (6.33%)” | “6/75 (8.00%)” | “1/79 (1.27%)” |
| Suicidal behaviour | “3/79 (3.80%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |
| Intentional self-injury | “2/79 (2.53%)” | “2/75 (2.67%)” | “1/79 (1.27%)” |
| Suicidal ideation | “2/79 (2.53%)” | “2/75 (2.67%)” | “0/79 (0.00%)” |
| Drug withdrawal syndrome | “1/79 (1.27%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |
| Depression | “0/79 (0.00%)” | “1/75 (1.33%)” | “0/79 (0.00%)” |
| Hospitalisation | “0/79 (0.00%)” | “1/75 (1.33%)” | “0/79 (0.00%)” |
| All-cause mortality | “0/79 (0.00%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |
Serious adverse events: company statement
Other adverse events with frequency of 5% or more: registry results
| Event | 25 mg | 10 mg | 1 mg |
|---|---|---|---|
| Any other adverse event | “60/79 (75.95%)” | “51/75 (68.00%)” | “50/79 (63.29%)” |
| Headache | “27/79 (34.18%)” | “16/75 (21.33%)” | “20/79 (25.32%)” |
| Nausea | “18/79 (22.78%)” | “7/75 (9.33%)” | “4/79 (5.06%)” |
| Fatigue | “12/79 (15.19%)” | “5/75 (6.67%)” | “7/79 (8.86%)” |
| Insomnia | “8/79 (10.13%)” | “11/75 (14.67%)” | “14/79 (17.72%)” |
| Anxiety | “7/79 (8.86%)” | “13/75 (17.33%)” | “3/79 (3.80%)” |
| Mood altered | “7/79 (8.86%)” | “3/75 (4.00%)” | “1/79 (1.27%)” |
| Dizziness | “6/79 (7.59%)” | “1/75 (1.33%)” | “1/79 (1.27%)” |
| Back pain | “6/79 (7.59%)” | “0/75 (0.00%)” | “3/79 (3.80%)” |
| Suicidal ideation | “5/79 (6.33%)” | “3/75 (4.00%)” | “4/79 (5.06%)” |
| Myalgia | “5/79 (6.33%)” | “2/75 (2.67%)” | “1/79 (1.27%)” |
| Panic reaction | “4/79 (5.06%)” | “1/75 (1.33%)” | “1/79 (1.27%)” |
| Euphoric mood | “4/79 (5.06%)” | “5/75 (6.67%)” | “4/79 (5.06%)” |
| Thinking abnormal | “0/79 (0.00%)” | “4/75 (5.33%)” | “0/79 (0.00%)” |
Timing of suicidality events and dose-related events
Study limitations
Summary: functional unblinding, low-dose comparator without an active treatment, antidepressant washout, Week 3 primary endpoint
The authors state that interpretation is limited by the absence of an active comparator and the possibility of functional unblinding in participants who received a low dose, and that larger and longer trials, including comparison with existing treatments, are required. Published correspondence disputed the description of the trial as double-blind. The primary endpoint was at Week 3, and the authors state that in the 25 mg group, sustained response at 12 weeks was not generally supportive of the primary results. Participants tapered antidepressants at least two weeks before baseline and were asked to remain off them for at least 3 weeks after dosing; a commentary notes that many started other antidepressants after Week 3. The same commentary notes emergent suicidal ideation and behavior in the 25 mg and 10 mg groups and not in the 1 mg group, and the publication reports suicidal ideation or behavior or self-injury in all dose groups.
Authors' stated limitations: comparator and trial size
Authors' stated limitations: secondary analyses
Functional unblinding: published correspondence
Functional unblinding and expectancy in psychedelic trials
“While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Commentary: dose selection, psychedelic effects, and suicidality
“The findings support use of drug plasma levels to optimize psilocybin doses and to analyze dose-dependent variance in clinical response, instead of using oral dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most side effects (nausea, headache) were comparable between the 10 mg and 25 mg dose groups, but surprisingly, the paper is silent about psychedelic effects even though it reports such effects lasted about 6 h after taking psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, suicidal ideation and behavior history were comparable in all three dose groups prior to the study, but emergent suicidal ideation and behavior was observed in the 25 mg and 10 mg groups and not in the 1 mg group (employed as an active comparator instead of a placebo).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commentary: antidepressant restart after Week 3
“Individuals who participated in the study were asked to stay off other psychotropic medications for the first 3 weeks and most complied.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 25 mg dose showed efficacy compared with 1 mg daily at 3 weeks, and this continued until 12 weeks, even though many patients started other antidepressants after week 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antidepressant washout before dosing
“It has been suggested that the recent use and discontinuation of antidepressant drugs compromises the action of psilocybin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As evidence is only available from small or uncontrolled samples, this post hoc analysis investigated this using data from the largest, phase II, randomized controlled trial of psilocybin treatment to date.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Commentary on the therapeutic alliance analysis
“While the authors conclude that alliance did not meaningfully contribute to treatment efficacy, we argue that this interpretation is not supported by the reported results, which are, in addition, shaped by methodological decisions that obscure relevant effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, we highlight unexplained deviations from the study protocol that warrant scrutiny.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
COMP004
Objective
Published study aim
“Here, we report findings from COMP 004, a 52-week observational follow-up of patients from COMP 001 and COMP 003, a small open-label study of the coadministration of 25 mg COMP360 with continuing antidepressant treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study dates and identifiers
| Item | Registry record |
|---|---|
| Other study ID | “COMP004” |
| Study start (actual) | “2020-07-20” |
| Primary completion (actual) | “2022-08-11” |
| Study completion (actual) | “2022-08-11” |
| Last update posted | “2022-09-22” |
Study design
Registered design
| Item | Registry record |
|---|---|
| Study type | “Observational” |
| Observational model | “Ecologic or Community” |
| Time perspective | “Prospective” |
| Official title | “Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)” |
Follow-up structure and duration
Eligibility criteria
Registered eligibility criteria
Treatment
Interventions received in the parent studies
No study drug administered during follow-up
Study outcomes
Rationale for using time to depressive event as the primary endpoint
Primary endpoint definition
Registered outcome measures
Regulatory expectations for durability after a single psychedelic dose
Time to relapse in regulatory maintenance designs
Time to relapse as the primary endpoint in a treatment-resistant depression trial
“Cumulative distribution of time to relapse during the maintenance phase among patients who achieved stable remission (primary efficacy end point) and those who achieved stable response without remission (secondary end point) was estimated by the Kaplan-Meier method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relapse was defined as a MADRS total score of 22 or higher for 2 consecutive assessments separated by 5 to 15 days or hospitalization for worsening depression, suicide attempt, suicide prevention or completed suicide, or another clinically relevant event suggestive of relapse (assessed by a relapse adjudication committee).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical relevance of time-to-event endpoints in psychiatric conditions
“The actual outcome in survival analysis is ‘time to event’, yet, in the mental health field, there has been little consideration of whether a temporary delay to relapse is clinically relevant in a condition that can last for decades.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They inevitably lead to differences in time to relapse, even when there is little or no difference in the cumulative risk of relapse at final follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment: registry record
| Enrollment type | Participants |
|---|---|
| Actual | “66” |
Planned enrollment
No evidence found.
Description of analysis sets
Post hoc analysis set: participants who entered COMP004
Results
Participant disposition
Baseline characteristics
Antidepressant use at entry
Efficacy results
Median time to depressive event: published analysis
“For all COMP 001 patients (n = 233), median time to depressive event was greater for the 25 mg group (92 days) compared to the 10 mg (83 days) and 1 mg (62 days) groups, with the majority of participants having had a depressive event by Week 12 (25 mg n = 37/75, 10 mg n = 38/79, 1 mg n = 44/75).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Median time to depressive event: annual report figure for the 10 mg group
Median time to depressive event: post hoc analysis of enrolled participants
“The post hoc supplementary analysis of those who enrolled in COMP 004 from COMP 001 exhibited the difference between groups more strikingly (25 mg, 189 days; 10 mg, 43 days; 1 mg, 21 days); however, only 10 participants experienced a depressive event post-COMP 004 enrollment (25 mg n = 6, 10 mg n = 3, 1 mg n = 1) from COMP 001 and none from COMP 003.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Median time to depressive event: quarterly results statement
Health-related quality of life and patient-reported outcomes
Safety results
Serious, ongoing, and suicidality adverse events: company statement
Study limitations
Summary: observational design, selected subgroup, few events, post hoc analysis
COMP004 was an observational follow-up that enrolled 66 participants who had completed COMP001 or COMP003, 58 of them from COMP001. The prespecified primary analysis covered all COMP001 participants, and the analysis restricted to enrolled participants was post hoc and based on 10 depressive events after enrollment. At entry, more participants in the 1 mg group were taking antidepressant medication (10, compared with 9 in the 10 mg and 6 in the 25 mg group). The published and Form 10-K medians for the 10 mg group differ (83 and 86 days). The authors state that larger long-term studies are required, and FDA guidance describes blinded long-term follow-up with prespecified retreatment criteria as the most informative design.
Authors' stated limitations: few events and need for larger studies
Unblinded observational follow-up
COMP003
Objective
Safety, tolerability, and efficacy of COMP360 adjunctive to an SSRI
“This phase II, exploratory, international, fixed-dose, open-label study explored the safety, tolerability, and efficacy of a synthetic form of psilocybin (investigational drug COMP360) adjunct to a selective serotonin reuptake inhibitor in participants with TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With the development of psilocybin specifically as a treatment for TRD, it is important to test the impact of chronic antidepressant treatment on the antidepressant effects of psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This outcome will inform whether it is necessary to withdraw people from antidepressant drugs prior to administering psilocybin for a safe or therapeutic effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study period and sites in Ireland and the United States
“This was a phase II, exploratory, fixed-dose, open-label study conducted between August 2020 and September 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The protocol was approved by ethics committees at two sites located in Ireland and the United States (US): the Clinical Research Ethics Committee of the Cork Teaching Hospitals (CREC), and the Advarra Center for IRB Intelligence (CIRBI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry dates and locations
| Field | Registry entry |
|---|---|
| Study start (actual) | “2020-08-10” |
| Primary completion (actual) | “2021-10-14” |
| Study completion (actual) | “2021-10-14” |
| United States site | “Kadima Neuropsychiatry Institute” |
| Ireland site | “Sheaf House, Tallaght Hospital” |
Study design
Open-label, single-arm, fixed-dose design
“This trial explored the safety and efficacy of a single dose of 25 mg of the investigational drug COMP360, a proprietary pharmaceutical-grade synthetic psilocybin formulation, optimized for stability and purity, adjunct to an antidepressant drug in participants experiencing a current episode of treatment-resistant MDD (EudraCT number: 2018 002377; Clinicaltrials.gov identifier: NCT04739865).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“COMP360 was supplied by the sponsor, COMPASS Pathfinder Ltd (a subsidiary of COMPASS Pathways plc), London, UK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sponsor supervised the study which was conducted by a contract research organization (Worldwide Clinical Trials, Nottingham, UK, and North Carolina, US).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening, administration, and follow-up periods
“Eligible participants entered the screening period and attended the clinic weekly for three weeks prior to the psilocybin administration session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were followed up for three weeks to monitor safety and efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recruitment alongside the phase 2b trial
“Participants entered this study having been previously pre-screened for our phase IIb clinical trial (COMP 001), which was not an open label study, and the current trial (COMP 003) simultaneously.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In COMP 001, 428 patients were screened and 233 were found to be eligible and underwent randomization having successfully withdrawn from any antidepressant drug as required by the protocol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients unable or unwilling to complete medication withdrawal at the two participating sites, or those who had a preference to be screened for COMP 003 instead, were considered for this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria: treatment-resistant episode of major depressive disorder
“This study recruited adults aged 18 years or older who were outpatients and referred by practitioners from specialized psychiatric services or word of mouth from primary care services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were experiencing TRD, defined by meeting the Diagnostic and Statistical Manual of Mental Disorders (5th edition) criteria of single or recurrent episode of MDD (if first single episode, duration >3 months ≤2 years was required) without psychotic features and with at least moderate symptom severity (Hamilton Depression Rating Scale, 17 item [HAM-D-17] >18) at Screening and Baseline, and having failed to respond to an adequate dose and duration (>8 weeks) of two to four pharmacological treatments for the current episode, including their current SSRI” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria: stable treatment with a single SSRI
“Participants were taking a locally approved therapeutic dose of a single SSRI with at least 75% adherence for a minimum of six weeks prior to taking part and were asked to continue this treatment for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Permitted SSRIs included citalopram, escitalopram, fluoxetine, paroxetine, sertraline, vilazodone, and vortioxetine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria: psychiatric comorbidity, suicide risk, and other antidepressants
“Participants taking multiple antidepressant therapies were excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants experiencing a major comorbid psychiatric disorder or suicide risk were excluded based on clinical assessment, medical records, the Mini International Neuropsychiatric Interview (version 7.0.2), the McLean screening instrument for borderline personality disorder, and the Columbia-Suicide Severity Rating Scale (C-SSRS)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria in the registry record
Treatment
Single 25 mg dose during a monitored session
“The administration session (Day 1) consisted of a single administration of psilocybin 25 mg which could be administered to up to six participants in different rooms simultaneously.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each participant was accompanied by a lead therapist, with whom they had completed preparation, for the six- to eight-hour session to ensure physical and psychological safety and encourage the participant to remain attentive to the natural unfolding of their subjective experience, while avoiding active guidance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An assisting therapist was available within the vicinity to step in at any time if the lead therapist needed to leave or additional support was required, and a study psychiatrist was on site.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blood pressure was monitored continuously using a finger cuff device.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants wore eyeshades and headphones with a specifically designed playlist of music to assist in directing their attention internally.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preparation and integration sessions
“Preparation for the psilocybin experience was conducted by a therapist who was trained by the sponsor through a specially devised program” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Preparation took place over three sessions, during which the therapist built trust with the participant, explained the trial design and procedures, provided psychoeducation, and helped to prepare the participant for the psilocybin experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Day 2 and Week 1 following administration, participants completed an integration session with their lead therapist who encouraged them to derive their own solutions and insights from the psilocybin experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continued SSRI treatment and simultaneous sessions
“All participants continued their SSRI medication throughout the follow-up period and to the end of the study (Week 3); two participants on escitalopram increased their dose (10–20 mg) during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two psilocybin administration sessions (Day 1) involved simultaneous administration, where two participants were administrated at the same time (in separate rooms) in each session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Primary endpoint definition and scale range
“The primary efficacy end point was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from Baseline (Day -1) to three weeks post-psilocybin administration (Week 3)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total scores in the MADRS range from 0-60, with higher scores indicating greater severity of depression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remote blinded independent rating
“The MADRS was administered by a remote, blinded independent rater, following the structured interview guide” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“at Baseline (Day -1), Day 2 and Weeks 1, 2, and 3 to ensure standardization of administration and questions (service was provided by Worldwide Clinical Trials).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoints: response, remission, and clinician global ratings
“Key secondary end points included the proportion of participants with a response (defined as a ≥50% improvement in MADRS total score from Baseline) and remission (defined as a MADRS total score ≤10) at Week 3, change from Baseline in Clinical Global Impression–Severity (CGI-S) score at Week 3” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CGI-S is a 7-point rating scale of severity based on clinical judgment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
No formal sample size calculation
“No formal sample size calculations were performed for this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nineteen participants were dosed and the mean Baseline MADRS total score was 31.7 (SD = 5.77).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry enrollment
| Field | Registry entry |
|---|---|
| Enrollment (actual) | “19” |
Description of analysis sets
Safety, full analysis, and per-protocol sets
“Safety analyses were performed on the safety analysis set which included all participants who received psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Efficacy analyses were performed on the full analysis set which included all participants who received psilocybin and had at least one post-Baseline efficacy assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All enrolled participants were included in the safety and full analysis sets and one participant was excluded from the per- protocol analysis set due to violation of exclusion criterion two: Prior electroconvulsive therapy and/or ketamine for current episode” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive analysis and missing data
“There was no imputation for missing efficacy data and the observed data were used in statistical analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary efficacy end point (change from Baseline to Week 3 in the MADRS total score) was evaluated with the use of descriptive summaries using statistics for continuous variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, the secondary and exploratory efficacy end points were also summarized descriptively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Enrolled, dosed, and completed
“Nineteen out of 24 enrolled participants with TRD were dosed and completed the study - there were no post-treatment withdrawals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The stable and ongoing SSRIs included sertraline, escitalopram, fluoxetine, vilazodone, paroxetine, and citalopram” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographic and clinical characteristics, safety analysis set
Depression severity and episode duration at baseline
“The length of current episode of depression was greater than one year for 84.2% of participants, and 36.8% had experienced 3 or 4 treatment failures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Baseline the MADRS total score was classified as severe (total score ≥31) for 57.9% of participants and the mean MADRS total score was 31.7 (SD = 5.77)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Baseline the mean CGI-S score was 4.3 (SD = 0.99) which falls into the ‘moderately ill’ range (score = 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Primary endpoint: MADRS change from baseline at Week 3
“The mean MADRS total score at Week 3 was 16.8 (95% confidence interval [CI], 11.2–22.4) which equated to a clinically meaningful mean change from Baseline of −14.9 (95% CI, −20.7 to −9.2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This improvement was apparent at Day 2 and maintained throughout the three-week follow-up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The results from per-protocol analysis of the primary end point were consistent with the full analysis set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A reduction in every item in the MADRS was apparent from Baseline to Week 3” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MADRS response and remission
“Response (≥50% reduction from Baseline MADRS total score) at Week 3 was evident in eight (42.1%) participants and was sustained throughout the follow-up period for 63.2% at Day 2, and 57.9% at Weeks 1 and 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The same 42.1% of participants who were responders at Week 3 were also remitters (MADRS total score of ≤10) at Week 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Remission rates remained high throughout the follow-up period for 52.6% at Day 2, 47.4% at Week 1, and 42.1% at Week 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinician global impression of severity and improvement
“The mean CGI-S score at Week 3 was 2.9 (SD = 1.84) which equates to a −1.3 (SD = 1.29) change from Baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Proportion of responders on the CGI-S were 42.1% at Day 2, 63.2% at Week 1, 57.9% at Week 2, and 52.6% at Week 3” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fourteen participants (73.7%) were considered at least minimally improved (CGI-I score ≤3) by clinicians from Baseline to Week 3 and seven participants (36.8%) were considered responders (score or 1 or 2) at Week 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Authors' comparison with the phase 2b trial
“in fact, the response and remission rates were higher in the current study (42% response and remission rates at Week 3 verses 37% and 29%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This indicates that antidepressant drug withdrawal is not a prerequisite for a therapeutic response to psilocybin in this patient group, despite most previous trials including withdrawal as a standard procedure” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Acute psychedelic experience on the Five-Dimensional Altered States of Consciousness questionnaire
“Alterations of consciousness on the 5D-ASC were observed in every dimension including visual restructuralization, oceanic boundlessness, reduction of vigilance, and to a lesser extent anxious ego dissolution and auditory alterations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Health-related quality of life: EQ-5D-3L and EQ-VAS
“Participants’ EQ-5D-3L mean total score at Baseline was 0.51 (SD = 0.333) and improved by an average of 0.18 (SD = 0.310) by Week 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The EQ-VAS mean score at Baseline was 49.0 (SD = 17.45) and improved by an average of 13.7 (SD = 18.09) by Week 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-reported depression: QIDS-SR-16
“The QIDS-SR-16 mean total score at Baseline was 16.5 (SD = 5.04), indicating severe depression, and decreased by an average of 6.9 (SD = 6.05) by Week 3 where the mean total score indicated mild depression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety and affect: GAD-7 and PANAS
“The GAD-7 mean total score at Baseline was 12.9 (SD = 5.94) and decreased by an average of 4.1 (SD = 4.90) by Week 3, which is considered a clinically meaningful improvement in anxiety symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean Baseline score for positive affect was 19.3 (SD = 7.22) and increased by an average of 8.1 (SD = 10.58) by Day 2, and mean Baseline score for negative affect was 24.3 (SD = 10.26) and decreased by an average of 7.5 (SD = 6.79) by Day 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Treatment-emergent adverse events from Day 1 to Week 3, safety analysis set
Onset, duration, and headache
“Seventeen TEAEs were reported for 12 participants (63.2%), none of which were considered serious, or led to study withdrawal” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eleven of these TEAEs, which were experienced in nine participants (47.4%), had an onset of Day 1 (psilocybin administration day), and eight resolved on the same day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAE reported was headache (six events; six participants [31.6%]) which had an onset of Day 1 (n = 4) or Day 2 (n = 2) which were predominantly transient, reported as mild and moderate in five and one participants, respectively, and resolved on their own or with standard medication (paracetamol and ibuprofen) on the same day or day after.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All TEAEs resolved before the end of the study (Week 3), and none had a duration exceeding seven days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure increase treated with clonidine
“Three participants had a TEAE of blood pressure increased which were considered related or possibly related to study treatment, two were severe and treated with clonidine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One of these patients experienced chest heaviness and headache (also relieved by clonidine).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no specific parameters for administering clonidine and it was down to investigator discretion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicidal ideation and behavior
“There were no reports of active suicidal ideation with plan or intent to act, attempts, or self-injurious behavior at Baseline or during the study and follow-up period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the follow-up period, one participant who was disappointed by their lack of response and quality of psychedelic experience invoked concern regarding their mental state during a conversation with their non-study therapist, which prompted the therapist to initiate an involuntary assessment of the participant at a local emergency department.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After evaluation by a psychiatrist in the emergency department, the participant was deemed to not be a danger to themselves and not in need of hospital admission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory tests and electrocardiograms
“There were no clinically meaningful shifts from Baseline in clinical laboratory tests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No participant had treatment-emergent clinically important ECG values or increases in QTcF interval from Baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: open-label single-arm design, small sample, short follow-up, blood pressure measurement, sponsor analysis
The authors state that the study was limited by its small size, open-label design and absence of a comparator, a sample that was not demographically diverse, and the exclusion of participants with high suicide risk or current hospitalization, and that the open-label design may have influenced participant expectations. Nineteen participants were dosed, no formal sample size calculation was performed, efficacy was summarized descriptively, and follow-up lasted three weeks. Blood pressure elevations were recorded with a finger cuff system that was not accurately calibrated. The sponsor performed the data review, interpretation, and post hoc analyses, and several authors are current or past employees of COMPASS Pathfinder. The authors state that the findings need confirmation in a larger, double-blind, comparator-controlled study.
Authors' stated limitations
“The present study was limited by its small size, open-label design and absence of a comparator, the lack of a demographically diverse sample, and the exclusion of participants with high suicide risk or current hospitalization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is possible that the open-label design influenced participant bias and expectations towards the study treatment, and definitive comparisons with studies that included a withdrawal from SSRIs is not necessarily valid.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The findings will need to be confirmed in a larger, double-blind, comparator-controlled study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure measurement
“Unfortunately, we cannot give an accurate measure of the blood pressure elevation that undoubtedly occurred, because the finger cuff system was not accurately calibrated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“but these specific instances were recorded with a system which may not have been properly calibrated and were not checked by conventional cuff auscultation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor role in analysis and interpretation
“Review of the data, interpretation, and post-hoc statistical analyses and were performed by the sponsor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GMG, MC, LM, SM, HS, CS, SCS, JT, SW, and EM are current or past employees of COMPASS Pathfinder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PsiDeR
Objective
Feasibility of a placebo-controlled randomized design
“We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present trial built upon this pilot, exploring the feasibility of a randomized controlled trial (RCT) design that included a placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary objective in the protocol
“The primary objective is to evaluate the feasibility of a randomised, controlled trial design, in which a single dose of psilocybin 25 mg PO versus placebo, is given to adult participants with treatment resistant MDD (TRD), under psychologically supportive conditions, with 6 weeks of follow-up, by measuring recruitment rates, dropout rates and by estimating the variance of the primary outcome measure (Montgomery Asberg Depression Rating Scale (MADRS)) to inform on the design of a phase 3 trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Recruitment period and setting
“Between 21 June 2021 and 3 July 2024, 75 potential participants consented and were screened for eligibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Study visits were carried out initially at King’s College Hospital Clinical Research Facility and, subsequently, a refurbished community mental healthcare and research setting in the local community.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Halfway through recruitment, we moved to a refurbished community mental health team setting in a residential area, close to the local hospital.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recruitment to this trial was severely delayed by the impact of the COVID-19 pandemic, although the trial did recruit to target.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry dates and location
| Field | Registry entry |
|---|---|
| Study start (actual) | “2021-06-21” |
| Primary completion (actual) | “2024-12-18” |
| Study completion (actual) | “2024-12-18” |
| Location | “Clinical Research Facility, King's College Hospital” |
Planned trial period in the protocol
“The trial is taking place between September 2020 and September 2023 in a single centre in London, UK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because of the impact of the COVID-19 pandemic, the recruitment period may be extended, subject to necessary approvals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Single-site, double-blind, placebo-controlled feasibility trial
“This was a parallel-group, two arm, double-blind, randomized, placebo-controlled phase 2 feasibility trial undertaken at one NHS site in the UK (South London and Maudsley NHS Foundation Trust).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An open-label extension was also offered to all participants, lasting a further 12 weeks after the 6-week RCT follow-up period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sponsor of the trial was the South London and Maudsley NHS Foundation Trust and King’s College London.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“COMP360 psilocybin—a proprietary, pharmaceutical-grade synthetic psilocybin formulation—and matching placebo capsules were supplied by COMPASS Pathfinder Ltd., a subsidiary of COMPASS Pathways plc, which had no role in the design, conduct or analysis of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This trial was funded by the National Institute for Health and Care Research (NIHR) Clinician Scientist Programme (CS-2017-17-007).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Randomization by minimization and masking
“Participants were randomized (1:1) to receive 25-mg psilocybin or placebo, with the sequence generated using minimization by sex (male, female), age (25−59, ≥60) and past psilocybin use (yes, no), by a web-based service hosted by the King’s Clinical Trials Unit (KCTU) and concealed from the trial team.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants, researchers and the senior statistician (B.C.) were masked to treatment allocation until database lock.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Choice of an inactive placebo
“An inactive placebo control allows for a better characterization of safety signals in psychedelic trials and does not adversely affect feasibility aims; hence, it was chosen for this trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In discussion with the funders of this trial, we decided to use a true placebo control to measure the difference in AE rate and the variance in the primary depression outcome measure without the difficulties implied by an active control.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria: age, depression severity, and prior treatment
“Eligibility criteria for participants included age 25−80 years, fluency in English, meeting DSM-5 criteria for a current episode of MDD, a 17-item Hamilton Depression Rating Scale (HAM-D-17)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“score of ≥14 and an inadequate response to ≥2 therapeutic antidepressant trials or ≥1 antidepressant trial and ≥1 psychotherapy trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no upper limit on the number or type of previous treatments permitted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For those aged ≥60 years, the first episode of depression must have started prior to their 60th birthday.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria
“Exclusion criteria included a DSM-5 diagnosis of bipolar disorder, psychotic disorder, drug or alcohol dependence syndrome, personality disorder or dementia; suicide attempt in the past year; any clinically significant medical diagnoses or biochemical or electrocardiographic abnormalities deemed incompatible with psilocybin treatment; personal circumstances or behavior judged to be incompatible with establishment of rapport or safe exposure to psilocybin; women of childbearing potential not using adequate contraception; women who were pregnant or breastfeeding; those unable to give informed consent; those enrolled in another drug trial; and hypersensitivity to the investigational medicinal product, any of the excipients or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Single 25 mg dose of COMP360 or matched placebo
“COMP360 psilocybin and placebo were administered as five capsules, matched for appearance, weight, color, texture and smell.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants self-administered either 25-mg COMP360 psilocybin or placebo via oral administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were accompanied by a therapist and chaperone for approximately 6 hours within a quiet room with a bed and adjustable lighting within the research facility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were given an optional eye mask and earphones through which they listened to a curated playlist of music.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A trial doctor determined suitability for discharge at the end of the day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Withdrawal of antidepressants and psychological preparation
“Participants determined eligible at screening (V1) entered a screening and preparation phase (lasting 1−8 weeks), during which they were withdrawn from antidepressant, antipsychotic or mood-stabilizing drugs and had sessions of psychological preparation and psychoeducation with a trial therapist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Integration therapy and open-label extension
“For 6 weeks after the dosing visit, participants met with the study team to complete follow-up assessments and engage in time-limited integration therapy (1 day (V4), 1 week (V5), 3 weeks (V6) and 6 weeks (V7) after dosing).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As part of the extended design of this trial, at 6-week follow-up all eligible participants were invited to take part in a 12-week open-label extension, the results of which will be published elsewhere.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using recruitment and retention rates as the primary endpoint
Primary feasibility outcomes
“Primary outcomes were measures of feasibility: recruitment rates, dropout rates and an estimate of the variance of the MADRS” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was designed as a feasibility study to estimate the dropout rate (20%) with a 95% CI of ±10.1% (9.9−30.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No hypothesis testing was undertaken.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale in the protocol: acceptability of a placebo-controlled design and variance for a future efficacy trial
“However, this study was not blinded and did not have a placebo control group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, it could not be determined from the open label design whether a randomised, placebo-controlled design investigating psilocybin would be acceptable to patients with TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A further purpose of this trial was to estimate the variance of the primary outcome measure between groups to inform a power calculation for a future efficacy trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Allows a robust measurement of the variance in the primary outcome measure between groups to inform an efficacy trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Feasibility parameters reported
“To evaluate recruitment and other feasibility parameters, the following are reported alongside 95% CIs: proportion eligible out of number screened; proportion randomized out of number consented; proportion completing at least the MADRS at each follow-up visit out of number randomized (overall and by arm); proportion attending the dosing visit out of number randomized (overall and by arm); and proportion receiving all five capsules/tablets out of number randomized (overall and by arm).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Depression outcome: MADRS by blinded independent raters at Week 3
“The primary outcome measure for depression is the Montgomery Asberg Depression Rating Scale collected by blinded, independent raters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint is at 3 weeks, and the total follow-up is 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary clinical outcomes
“Secondary outcomes at weeks 1, 3 and 6 follow-up included MADRS total scores; proportions of participants in each group who met criteria for clinician-rated response to treatment (defined as a ≥50% decrease in MADRS score from baseline) and remission (defined as a MADRS score ≤10)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Target sample size and its basis
“The target sample size was 60 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All 60 participants were included in primary feasibility analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant withdrew in the placebo arm before contributing follow-up MADRS data and was, thus, excluded from mixed models.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since the study is exploratory, formal sample size calculations were not undertaken.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sample size selected was informed by published work that models processes of parameter estimates for continuous measures from early phase trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This is considered sufficient to test the intervention and provide adequately reliable estimates of recruitment rate and loss to follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Intention-to-treat analysis and mixed models
“Analyses were intention to treat: all participants were analyzed as randomized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For secondary continuous clinical outcomes, the adjusted mean difference between arms was estimated in mixed-effects linear regression models.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Follow-up values were fit simultaneously and predicted by the fixed effects of trial arm, baseline assessment, minimization factors (sex, age group, prior psilocybin use), time (categorical) and an arm × time interaction term to allow estimates of the treatment effect at each follow-up point.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary binary outcomes were analyzed using mixed-effects logistic regression models with random intercept at the participant level and adjusting for the fixed effects, as stated previously.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Screening, randomization, and withdrawal
“Sixty participants were randomized to either psilocybin or placebo arms; 30 participants were allocated to each arm” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 75 participants consented and screened, 62 were eligible (83%, 95% confidence interval (CI): 72−90%), and 60 were randomized (80%, 95% CI: 69−88%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All randomized participants attended the dosing visit, and 59 of 60 participants completed the MADRS at each timepoint, as the only missing observation was the one participant in the placebo arm who had withdrawn prior to week 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant withdrew from the placebo arm; the participant no longer wished to participate for personal reasons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Minimization factors and baseline demographics by arm
Treatment resistance and chronicity
“Median Maudsley Staging Method (MSM) scores at screening indicated that most participants scored within the moderate range for treatment resistance, with a chronic course of illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, patients in this trial had been ill for 20 years and showed moderate levels of treatment resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Primary feasibility outcomes
“No success metrics were set, but eligibility and randomization rates were high.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 97.5% one-sided CI (with an upper bound of infinity) is given if the proportion was 100%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MADRS adjusted mean difference between arms
“At week 3, the between-group difference in the MADRS was −10.41 (95% CI: −14.86 to −5.95), indicating a clinically significant improvement in depression in the psilocybin arm compared to the placebo arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The between-group difference in the MADRS at week 3 was sustained at week 6, with an adjusted mean difference of −12.92 points (95% CI: −17.37 to −8.47).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohen’s d is the mean difference between arms divided by pooled baseline standard deviation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MADRS response and remission
“At week 3, 1 (3%) participant in the placebo arm and 13 (43%) participants in the psilocybin arm met the cutoff for MADRS response, and 1 (3%) in the placebo arm and 12 (40%) in the psilocybin arm met the cutoff for MADRS remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These figures were sustained at week 6; however MADRS response increased to 15 (50%) participants in the psilocybin arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Adjusted mean differences in patient-reported outcomes
Self-reported depression response and remission
“At week 3, no participants in the placebo arm met criteria for Quick Inventory of Depressive Symptomatology Self-Report 16-item version (QIDS-SR-16) response compared to 15 (50%) in the psilocybin arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 6, one (4%) participant in the placebo arm and 13 (43%) participants in the psilocybin arm met QIDS-SR-16 response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant (4%) in the placebo arm and 12 (40%) participants in the psilocybin arm met the cutoff for QIDS-SR-16 remission at week 3 compared to two (7%) in the placebo arm and 10 (33%) in the psilocybin arm at week 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety, health state, functioning, and wellbeing
“at week 6, 5 of 30 (17%) psilocybin participants had GAD-7 scores ≥10 compared with 18 out of 29 (62%) placebo participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Self-reported depression severity was improved in the psilocybin arm compared to placebo at all follow-up timepoints, as were ratings of anxiety, overall health state, psychopathology and mental wellbeing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Nonserious adverse events during the randomized phase (randomization to Week 6)
Serious adverse events and relatedness
“In total, 287 nonserious AEs (123 in the placebo arm, 164 in the psilocybin arm) were recorded in the RCT phase” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four SAEs (one in the placebo arm, three in the psilocybin arm) were recorded: three during the open-label phase and one during the RCT phase” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over half of nonserious AEs (184 out of 287, 64%) were not related to study medication, and all but one SAE was deemed not related to study medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The remaining event, which occurred in the placebo arm, was deemed as possibly related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicidality and mania
“Psilocybin administration was well tolerated: AEs were mostly mild in severity and resolved by the end of the trial, and clinical safety scales measuring suicidality and mania did not show substantial changes across time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the present study, the proportion of patients reporting suicidal ideation on the Columbia−Suicide Severity Rating Scale (C−SSRS) was similar at baseline and at week 3 and week 6 follow-up, after an initial reduction at day 1 and week 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Proportions also appeared similar across arms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: functional unblinding, inactive placebo with little placebo response, feasibility design, single site, sample composition
PsiDeR was a single-site feasibility trial of 60 participants with 6 weeks of follow-up and no hypothesis testing. Blinding was assessed in a subsample of 23 participants after a measure was introduced part-way through the trial: 13 of 13 (100%) in the psilocybin arm and 7 of 10 (70%) in the placebo arm correctly guessed their allocation, and the authors state that “expectancy effects in both groups likely account for some of the between-group difference observed”. The placebo arm did not show meaningful reductions in MADRS or QIDS-SR scores, and the authors note that active placebos or subperceptual doses may be more appropriate for efficacy trials. The sample was highly educated, recruitment targets were not met for Black, African, Caribbean or Black British participants, and about half of participants used facilities opened under a later financial agreement with COMPASS Pathways.
Functional unblinding and expectancy
“Blinding was not upheld, with 100% of participants who received psilocybin and 70% of participants who received placebo correctly guessing their allocation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, expectancy effects in both groups likely account for some of the between-group difference observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Functional unblinding due to the subjective effects of psilocybin is an obvious limitation of this trial, as it is with all trials of drugs that have noticeable effects, as well as many psychological and behavioral interventions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, we used raters who were independent of the trial team to measure the primary outcome in this trial, and participants were asked not to discuss their beliefs about their allocation with the raters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite this, the limited assessment of blinding is a weakness of this trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding assessed in a subsample
“The adequacy of participant blinding was assessed using self-report visual analog scales of group allocation confidence, introduced part-way through the trial and, therefore, collected in only a subsample of participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 23 participants who were asked, n = 13 out of 13 (100%) in the psilocybin arm and n = 7 out of 10 (70%) in the placebo arm correctly guessed their treatment allocation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absence of placebo response and choice of control
“However, a part of this effect is likely attributable to a lack of response or remission in the placebo arm, with total MADRS and QIDS-SR scores not showing meaningful reductions across time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, other trial designs (that is, active placebos or subperceptual doses of the study drug) may be more appropriate for efficacy trials and will be considered in the design of a future trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“found more modest effect sizes comparing 1-mg to 25-mg psilocybin at week 3 than in the present trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sample composition and generalizability
“We largely met our recruitment targets in all ethnic groups, apart from in Black, African, Caribbean or Black British participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We note that our sample population is highly educated, with much higher proportions of participants with university degrees than in the general population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Together, these results suggest that a single dose of psilocybin may reduce depressive symptoms in MDD and TRD, although larger, and longer, scale studies are required to confirm the nature and durability of these effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single centre and rater independence in the protocol
“As this is a single-centre study, the findings are unlikely to be generalisable beyond the trial setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While raters of the primary outcome are independent of the study team, they are not independent of the institution undertaking the research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relationship between the trial facilities and COMPASS Pathways
“Although COMPASS Pathways did not financially support this study, a separate financial agreement 4 years subsequent to this study being funded resulted in the opening of the Centre for Mental Health Research and Innovation, the facilities of which were used (without cost) for about half of the participants in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EudraCT 2018-000978-30
Objective
Safety of simultaneous administration and effects on cognition
“The aim of this study was to explore the safety of simultaneous administration of psilocybin to healthy participants in the largest randomised controlled trial of psilocybin to date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study aimed to evaluate the safety and feasibility of simultaneous administration of single doses of either 10 or 25 mg doses of psilocybin compared with placebo in healthy participants, administered in a supervised setting with one-to-one psychological support, and to assess the short- and long-term effects of psilocybin on key domains of cognitive functioning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to study the safety and feasibility of this model of simultaneous administration as it could be a more effective, time- and cost-efficient model of treatment delivery, meaning more patients could potentially benefit from this treatment, if approved.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Single site in London, August 2018 to July 2019
“The first participant’s first visit date was August 17, 2018, and the last participant’s last visit date was July 19, 2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the NIHR/Wellcome Trust Clinical Research Facility at King’s College Hospital, where this study was undertaken.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Phase 1, randomized, double-blind, placebo-controlled design
“This was a phase 1, randomised, double-blind, placebo-controlled, between-groups study to evaluate the effects of single 10 and 25 mg doses of psilocybin compared with placebo in healthy participants, conducted at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK, sponsored by COMPASS Pathways (EudraCT number: 2018-000978-30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were followed up for 12 weeks after study drug administration” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was funded and sponsored by COMPASS Pathways, London, UK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stratified randomization with individual allocation within shared sessions
“Participants were stratified by sex and age (18–35 years old; >35 years old) and randomised in a 1:1:1 ratio using blocked randomisation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were randomised on an individual basis and therefore participants in the same dosing session could be allocated to different treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Healthy adults without recent psilocybin use
“The study recruited healthy participants (male or female; aged 18−65 years at screening) with no psilocybin experience within 1 year prior to enrolment; the study aimed to recruit up to 90 participants who met eligibility criteria at the screening visit (visit 1; day -56 to day -2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were recruited via online advertisements and word of mouth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inclusion criteria, psychiatric exclusion criteria (including current/history of psychiatric disorders, current/recent psychiatric medications, or other psilocybin-incompatible psychiatric or psychological conditions, as judged by the investigator), and medical exclusion criteria are listed in the Supplementary Methods.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Single oral dose of COMP360 10 mg or 25 mg, or placebo, as five capsules
“The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“COMP360 psilocybin was administered in this study, which is COMPASS Pathways’ proprietary pharmaceutical-grade synthetic psilocybin formulation that has been optimised for stability and purity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Group preparation, simultaneous administration session, and integration
“During this visit, participants attended a 2-h group preparatory session (involving all participants to be dosed the following day, a lead therapist and assisting therapists) and had a short (5–15 min) individual discussion with their assigned assisting therapist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Administration sessions generally lasted ~6–8 h, with psychological support available throughout from specially trained assisting therapists, who were supervised by a lead therapist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The simultaneous dosing involved each participant having a private space, for example, a bed separated by curtains within the same room, so they could focus on their own experience with minimal distractions, especially as participants were encouraged to wear eyeshades, earplugs and/or earphones for the duration of the administration session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were subsequently discharged and asked to return the following day (day 1; visit 4) for safety assessments and a discussion with their allocated therapist about the subjective experience during the administration session (integration session).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using CANTAB cognitive measures as the primary endpoint
Rationale for studying cognitive and emotional processing
“Psilocybin’s effects on cognitive function have not been widely or systematically studied.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neural correlates of cognitive and emotional processing are considered important therapeutic targets in the development of novel treatments for treatment-resistant depression and other mental disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given this unmet need for improved treatment of social and emotional functioning deficits, a better understanding of the short- and long-term effects of psilocybin on emotional processing and social cognition is required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, it has not yet been investigated whether the beneficial effects of psilocybin may also benefit general cognitive abilities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the potential for psilocybin as a treatment for a range of conditions, studying its effects on cognition is important.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary efficacy endpoints: CANTAB measures and social cognition scales
“The primary efficacy endpoints were short-term change from baseline (day -1) to day 8 in cognitive measures of attention, spatial and working memory and executive function” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“short-term change from baseline to day 8 in social cognition, emotional processing scales (comprising the Pictorial Empathy Test (PET); Reading the Mind in the Eyes Test (RMET); Scale of Social Responsibility (SSR); Social Value Orientation (SVO); and Toronto Empathy Questionnaire (TEQ)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“change from baseline to day 29 in the individual cognitive functioning assessments previously outlined; and long-term change from baseline to day 85 in social cognition, emotional processing scales.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANTAB global composite score as a safety endpoint
“Safety was assessed via endpoints which included cognitive function, assessed by CANTAB global composite score, and treatment-emergent adverse event (TEAE) monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cognitive function was measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB) global composite score change from baseline (day -1) to day 8 and 29, calculated from Z scores for each CANTAB measure (Paired Associates Learning-Total Errors Adjusted (PAL-TEA; a measure of episodic memory); Spatial Working Memory-Between Errors (SWM-BE; working memory); SWM-Strategy (SWM-S; executive function and planning); and Rapid Visual Information Processing A-prime (RVP-A’; sustained attention); a higher CANTAB global composite score indicates better cognitive function).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Familiarization session to limit practice effects
“At screening, participants underwent CANTAB assessments as part of a familiarisation session; this was included in the descriptive statistics but was excluded from statistical modelling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The purpose of familiarisation was to ensure that all the participants had a chance to practice the tests prior to the collection of the baseline data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary efficacy endpoints
“Secondary efficacy endpoints included dose-related differences in the cognitive effects of psilocybin at baseline, day 8 and day 29, measured by the CANTAB assessments RVP-Aʹ, SWM-BE, SWM-S, PAL-TEA; dose-related differences in the psychological effects of psilocybin at baseline, day 8 and day 85, measured by the social cognition, emotional processing scales; differences in the cognitive effects of psilocybin between psilocybin-naïve and -experienced participants at baseline, day 8 and day 29, measured by the CANTAB global composite score; and differences in PANAS after study drug administration on day 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample of up to 90 participants
“A sample size of up to 90 participants (30 per treatment group) was chosen to allow reasonable assessment of each of the planned endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was exploratory and therefore not adequately powered to detect statistical significance; as such p values are not reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 30 participants were randomised to receive 25 mg psilocybin, 30–10 mg psilocybin and 29 to placebo; 33 (37.1%) participants had prior psilocybin experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Safety, modified intent-to-treat, and per-protocol populations
“The Safety Population comprised all randomised participants who received study drug and was used for all summaries of participant accountability, demographic and baseline data, and safety information, including AE incidence and cognition endpoint analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The modified Intent-to-Treat (mITT) Population comprised all participants in the Safety Population who had at least one post-dose assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This population was used for emotional processing endpoint analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Per-Protocol (PP) Population comprised all participants in the Safety Population who did not have a major protocol deviation that was thought to significantly affect the integrity of the participant’s data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This population was used for the CANTAB primary endpoint analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mixed model for repeated measures
“The MMRM method utilises the observed data efficiently, handling missing data automatically, based on the assumption that data are missing at random, thus minimising bias in the estimates of treatment effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Randomized, dosed, and completed
“The study randomised 89 healthy participants (mean age, 36.1 years; 41 females, 48 males)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants randomised to both psilocybin arms completed the study; four (13.8%) placebo-treated participants did not complete all study visits (three were lost to follow-up; one was withdrawn following a protocol deviation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-five administration sessions were completed, with up to six participants dosed simultaneously per session (there were 2 sessions with one participant each, 3 with two, 5 with three, 11 with four, 2 with five and 2 with six).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Participant demographics, safety population
Efficacy results
CANTAB measures: least squares mean difference from placebo
“For PAL-TEA, SWM-BE and SWM-S, lower scores denote better performance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For RVP-A’ and CANTAB composite, higher scores denote better performance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no clinically relevant between-group differences in CANTAB global composite score, CANTAB cognitive domain scores, or emotional processing scale scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the CANTAB composite score, performance was worse than placebo for the 10 mg psilocybin group at day 8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, this result is due in part to the larger improvement in performance from baseline by the placebo group at day 8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the 10 mg psilocybin group, performance increased again by day 29 to a level similar to placebo suggesting no adverse effects of the 10 mg psilocybin dose compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Social cognition and emotional processing scales: least squares mean difference from placebo
“There was no difference between either psilocybin group and placebo in any social cognition and emotional processing scale (PET, RMET, SSR, SVO, or TEQ) scores at day 8 or day 85, relative to baseline” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings suggest that psilocybin does not exert any detrimental effect on the social cognition and emotional functions assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Positive and negative affect after dosing
“The placebo group showed a trend for a reduction in positive affect score from baseline to post-dose (least squares (LS) mean change = -5.0), which was not observed in either psilocybin group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conversely, the 25 mg psilocybin group showed a trend for an increase in LS mean negative affect score from baseline of 1.3, compared with no change in the 10 mg psilocybin and placebo groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Most frequent treatment-emergent adverse events and events of special interest, safety population
Overall incidence, relatedness, and duration
“In total, 511 TEAEs were reported during the 12-week study: 217 in the 25 mg psilocybin arm (reported by 29 (96.7%) participants), 203 in the 10 mg psilocybin arm (reported by 29 (96.7%) participants) and 91 in the placebo arm (reported by 26 (89.7%) participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 208, 188 and 77 were deemed by the investigator to be potentially related to study treatment in the 25 mg, 10 mg and placebo arms, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no serious TEAEs and no AEs led to withdrawal from the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across all AEs reported in all treatment arms throughout the 12 week study, 67% started and resolved on the administration day; the median duration of AEs was 1.0 day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety and substance-induced psychotic disorder on the day of dosing
“Four participants reported AEs of anxiety on the day of study drug administration (25 mg psilocybin, n = 2 (6.7%); 10 mg psilocybin, n = 1 (3.3%); placebo, n = 1 (3.4%))” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An AE of substance induced psychotic disorder was reported for a participant who became behaviourally disinhibited during the acute drug experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a medical assessment, 2.5 mg oromucosal midazolam was administered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The participant recovered with no sequelae and was discharged 11 h after receiving the study intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicidality on the Sheehan Suicidality Tracking Scale
“At baseline, all participants recorded an SSTS score of 0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During follow-up, no participants in the 25 mg psilocybin arm recorded an SSTS score > 0; however, one participant in the 10 mg psilocybin arm recorded a highest score of 1 during follow-up (reported at the day 29 visit).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This participant reported a TEAE of suicidal thoughts (one event), which started and resolved on day 19, was mild in severity and was deemed by the investigator to be possibly related to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory tests and vital signs
“There were four clinically significant clinical laboratory assessment findings, which were recorded as AEs (none of which prevented the participant from entering or continuing in the study).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no clinically significant findings in vital signs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: healthy participants, exploratory sample size, blinding not assessed, practice effects, sponsor involvement
The study enrolled 89 healthy participants who were typically highly educated, and 37% of the sample had previous psilocybin experience; the authors state that these factors and the small sample size could have limited generalisability and that the findings warrant investigation in clinical populations. The sample size was not powered to detect statistically significant differences, and p values were not reported. Blinding efficacy was not assessed, and the authors state that participants may have been able to determine their assigned treatment group. Practice effects could have influenced results, and outcomes were measured at day 8 and at day 29 or 85. The study was funded and sponsored by COMPASS Pathways, and several authors are employees or former employees of the company.
Exploratory design without power for efficacy comparisons
“however, our sample size was not powered to detect statistically significant differences in psilocybin efficacy between groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Instead, this was an exploratory evaluation of the efficacy and safety of psilocybin compared with placebo; caution should therefore be taken when interpreting these results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthy, highly educated, psilocybin-experienced sample
“The fact that participants were typically highly educated, and the small sample size, could have limited the generalisability of results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings warrant further investigation in clinical populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With thirty-five participants reporting previous use of psilocybin in this study, the proportion of participants with prior experience is greater than expected in the general population, thus additional caution should be taken when generalising these results to other populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding not assessed
“The efficacy of the blinding was not assessed in this study and therefore we cannot rule out the potential that guessing the treatment assignment influenced results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given psilocybin’s psychedelic effects, combined with the fact that 37% of the total sample had previous experience using psilocybin, it is possible that these participants may have been able to determine their assigned treatment group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Practice effects and assessment timepoints
“It is possible that practice effects could have influenced results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current study measured the short-term effects of psilocybin at day 8, and longer-term effects at day 29 or 85.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Future research would benefit from collecting outcomes at later time points post-dosing to gain a broader understanding of more long-term effects, and also acutely, either immediately after or during psilocybin administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor involvement
“ML-J, LM, SM, FS, SS, SW, HE and EM are employees or former employees of COMPASS Pathways plc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This assistance was funded by COMPASS Pathways plc, London, UK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote